Acidic Solution Virus Release for AAV Manufacturing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing non-enveloped viruses, such as adeno-associated viruses, face challenges in achieving high purity and efficiency without laborious operations, particularly in the steps preceding purification.

Innovation Solution

A method involving culturing virus-producing cells and exposing them to an acidic solution with a pH of 3.0-6.0, containing sodium or potassium ions, which allows for the efficient release and purification of non-enveloped viruses without physical cell disruption, using techniques like ultracentrifugation, chromatography, or ultrafiltration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If physical cell disruption methods (ultrasonic disruption, freeze-thaw) are used to release viruses from cells, then virus release efficiency is improved, but operation complexity and laboriousness increase

Engineering Contradiction:
Improvevirus release efficiencyVSAvoidoperation complexity
Core Design Contradiction:
ProductivityVSEase of operation

Solution Approach 1:

The patent replaces mechanical physical disruption methods (ultrasonic vibration, freeze-thaw cycles) with a chemical method using acidic solution (pH 3.0-6.0) to release viruses from cell pellets. The acidic solution dissolves the cell membrane and releases viral particles through chemical action rather than mechanical force, significantly simplifying the operation while maintaining high virus release efficiency.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Manufacturing precision

If multiple purification steps are performed to achieve high virus purity, then manufacturing precision is improved, but productivity decreases

Engineering Contradiction:
Improvevirus purityVSAvoidproduction efficiency
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent performs preliminary virus release directly in the acidic solution during the cell lysis step, so that virus particles are already in a dissolved and separated state before purification. This preliminary action in the acidic environment facilitates subsequent purification steps by reducing protein aggregation and improving virus solubility, thereby achieving high purity with fewer and more efficient purification steps.

Inventive Principle:
Principle #10Preliminary action

3Ease of manufacture

If conventional virus production methods are used, then ease of manufacture is maintained, but virus titer and purity are insufficient

Engineering Contradiction:
ImprovemanufacturabilityVSAvoidvirus titer and purity
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent changes the pH parameter of the solution to an acidic range (pH 3.0-6.0) during the virus release step, which fundamentally alters the chemical environment for virus extraction. This parameter change improves virus solubility, prevents protein aggregation, and enhances both virus titer and purity while maintaining ease of manufacture through a simple solution-based approach rather than complex process changes.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the efficient production of high-purity non-enveloped viruses, as demonstrated by increased genomic titer and reduced contaminating protein levels, facilitating their use in gene therapy and research applications.

Implementation Method 1

bringing the cell into contact with an acidic solution... does not comprise a physical cell disruption method

Methodology Applied
Scientific EffectChemical dissolution:

Implementation Method 2

The cell homogenate is subjected to a suitable step such as filtration with a filter, ultracentrifugation, chromatography, or ultrafiltration to purify the rAAV vectors

Methodology Applied
Scientific EffectCentrifugal separation: Centrifugal Separation

Implementation Method 3

The cell homogenate is subjected to a suitable step such as filtration with a filter, ultracentrifugation, chromatography, or ultrafiltration to purify the rAAV vectors

Methodology Applied
Scientific EffectChromatography: Chromatography

Implementation Method 4

The cell homogenate is subjected to a suitable step such as filtration with a filter, ultracentrifugation, chromatography, or ultrafiltration to purify the rAAV vectors

Methodology Applied
Scientific EffectUltrafiltration:

Data Source

PatentEP3020808B1Method for manufacturing adeno-associated virus
Publication Date: 2019.09.11 TAKARA BIO INC
  • EP3020808B1 patent drawingFigure 1
  • EP3020808B1 patent drawingFigure 2
  • EP3020808B1 patent drawingFigure 3

AI summary

The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.